Xilio Therapeutics IPO

10/22/2021

IPO

$117,600,000

We intend to use the net proceeds from this offering to advance the development of XTX202 through Phase 1 dose escalation and Phase 2 efficacy cohorts of our planned Phase 1/2 trial in patients with solid tumors; to advance the development of XTX301 through investigational new drug application, or IND, enabling studies, submission of an IND to the U.S. Food and Drug Administration and into initial Phase 1 development; to advance the development of XTX101 through Phase 1 dose escalation and to initiate activities for Phase 2 development; and to advance additional tumor-selective cytokine programs and for working capital and other general corporate purposes.

Publicly-held

Biopharmaceutical

828 Winter St.
Waltham, MA 02451
USA

Undisclosed

Not Recorded

Xilio is a Waltham, Massachusetts-based biopharmaceutical company focused on defeating cancer. The company's proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body -- a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang.